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Early detection of cysteine rich protein 61 (CYR61, CCN1) in toxic injury in animals, translation of an effective drug
urine following renal ischemic reperfusion injury. therapy for ARF from laboratory bench to bedside has
Background. Acute renal failure (ARF) has a high morbid- been difficult [1–4]. Numerous agents are effective inity and mortality. Many therapies have worked in animals but
animals [for example, atrial natriuretic peptide (ANP),were unsuccessful in clinical trials. The inability to diagnose
insulin-like growth factor-1 (IGF-1), thyroid hormone,ARF early may have impaired the success of these trials.
Method. We screened a subtraction library to search for endothelin antagonists], but have failed in clinical trials
potential disease markers that would be induced rapidly after [2, 3, 5, 6]. Only one agent, N-acetylcysteine, may prevent
renal injury. Mice and rats were subjected to 30 to 40 minutes
glomerular filtration rate (GFR) from decreasing afterof bilateral ischemia.
contrast administration [7]. The slow translation of re-Results. mRNA for Cyr61, a secreted growth factor-induc-
ible immediate early gene, was markedly up-regulated at two sults from bench to bedside, especially in the treatment
hours in the kidney but not other organs following renal isch- of existing ARF, might be caused by a heterogeneous
emia. In situ hybridization studies suggested Cyr61 was synthe- patient population, multiple and diverse types of renalsized in the proximal straight tubule. Cyr61 protein was ana-
insults, incorrect choice of culprit, or delayed detectionlyzed by capture with heparin beads followed by Western
of ARF [2, 3]. Early detection of ARF is difficult since,blotting. Induction of Cyr61 protein could be detected in the
kidney within one hour, peaked at four to eight hours, and in contrast to 30 to 40 years ago, it is no longer heralded
remained elevated for at least 24 hours following ischemia. by a fall in urine output. Instead, ARF is typically diag-
Cyr61 protein was detected in urine at three to six hours and
nosed by a progressive rise in serum creatinine overpeaked at six to nine hours after renal injury. Cyr61 was not
several days. Many patients with ARF, especially thosedetected after volume depletion, which is often difficult to
differentiate from ARF. in the intensive care unit (ICU), are volume overloaded
Conclusions. The secreted, cysteine-rich, heparin binding and that may dilute serum creatinine values and thus
protein Cyr61 is rapidly induced in proximal straight tubules delay diagnosis [3]. Unless patients are enrolled at thefollowing renal ischemia, and excreted in the urine where it
time of entry to the ICU [8], the mean plasma creatininemight serve as an early biomarker of renal injury.
in most ARF clinical trials is 3 to 4 mg/dL (for example
in [9]), indicating enrollment two to three days after the
original injury. Therapeutic agents are more effective inAcute renal failure (ARF) is a devastating disease that
animals when given early after injury, suggesting a nar-has a mortality rate of 25 to 70% [1]. Although much is
row “window of opportunity” such as that which occursknown about the pathogenesis of acute ischemic and
for myocardial infarction and stroke [3]. Therefore, it is
imperative to diagnose ARF as early as possible [2].
1 Drs. Muramatsu, Tsujie and Kohda performed equal work for this Detection of ARF by direct measurement of GFR is
study.
difficult because it requires a carefully timed urine collec-
Key words: ischemia, reperfusion, cyr61, biomarker, kidney injury. tion or injection of a tracer [2]. An ARF disease marker
that could be measured in blood or urine would be ex-Received for publication April 17, 2002
tremely useful in identifying patients with ARF so neph-and in revised form June 6, 2002
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We hypothesized that genes induced very early follow- a sodium deficient diet. Urine was collected from 24 to
27 hours for protein analysis (see below) and from 27ing renal injury might serve as markers of injury. Repre-
sentational difference analysis was used to screen for to 30 hours for sodium excretion. The animals were sacri-
ficed at 30 hours, at which time the animals had lostgenes that are induced rapidly following renal ischemia/
reperfusion, since human ARF is caused or aggravated greater than 8% of body weight, plasma creatinine was
modestly increased (0.4 mg/dL in volume depletion vs.by hypotension or renal ischemia in about 50% of pa-
tients [1, 10]. To increase the yield of native kidney 0.2 in normal rats), urine sodium was 10 mmol/L, and
the fractional excretion of sodium was 0.05%.proteins, the screen was performed at two hours after
ischemia, when only sparse leukocyte infiltration has oc-
Representational difference analysis of cDNAcurred. We confirmed that several intermediate early
genes (HSP70, EGR-1) were rapidly and transiently in- The outer medullary was hand dissected from normal
and ischemic kidney, total RNA extracted by RNAzolduced following renal ischemia [11, 12]. We also detected
cysteine rich protein 61 gene (Cyr61), which was origi- (ISO-TEX Diagnostics, Friendswood, TX, USA), mRNA
purified, cDNA synthesized, and polymerase chain reac-nally identified as a growth factor-inducible immediate
early gene in fibroblasts [13]. Cyr61 is a secreted heparin- tion (PCR)-based subtractive hybridization (PCR-select
cDNA subtraction kit; Clontech, Palo Alto, CA, USA)binding protein that may be involved in tissue growth
and repair [14, 15]. Since Cyr61 is a secreted protein, was performed. The final PCR product was subcloned
into a cloning vector (AdvanTAge; Clontech) and usedwe hypothesized that it might be detected in the urine
following injury. We took advantage of its heparin affin- to transform bacteria. One hundred and twenty colonies
were randomly picked, and DNA was purified (Wizardity to develop an assay for Cyr61 protein. Since ARF
(clinically diagnosed as acute tubular necrosis) and pre- Minipreps; Promega, Madison, WI, USA). One hundred
clones were screened for up-regulation using a cDNArenal azotemia (reversible volume depletion) can be dif-
ficult to distinguish clinically, Cyr61 also was measured dot blot probed with non-radioactively labeled mRNA
from a sham and ischemic kidneys from an independentafter volume depletion.
experiment. The clones exhibiting the most dramatic up-
regulation were sequenced, PCR primers were synthe-
METHODS
sized, and temporal regulation confirmed by reverse tran-
Animal models scription (RT)-PCR (data not shown). Several clones
exhibited large increases (EGR-1, HSP70, and Cyr61).Male Sprague-Dawley rats and Balb/c mice were pur-
chased from Harlan Sprague Dawley Inc. (Indianapolis, Since the former are known to increase following renal
ischemia [11, 12], we focused on Cyr61.IN, USA) or the National Institutes of Health (NIH;
Frederick, MD, USA). All animals had free access to
RNA blot analysiswater and food (4% mouse-rat diet; Harlan Sprague
Dawley Inc.). Animal care followed the criteria of the Total RNA (7g) was fractionated via electrophoresis
on a 0.9% agarose-formaldehyde gel and transferredUniversity of Texas Southwestern Medical Center and
the NIH for the care and use of laboratory animals in onto a nylon membrane. The equality of RNA samples
after transfer to the membrane was substantiated byresearch. For the representational difference analysis, a
rat was anesthetized with an IM injection of 100 mg/kg staining with ethidium bromide. Membranes were fixed
by baking at 80C, then prehybridized at 42C in 50%ketamine, 10 mg/kg xylazine, and 1 mg/kg acepromazine,
and placed on a heating table kept at 39C to maintain formamide, 0.5% sodium dodecyl sulfate (SDS) and 5 
Denhardt’s solution, 5  standard sodium citrate (SSC),body temperature. The left kidney was removed, and
the right renal pedicle was cross-clamped for 40 minutes. and 0.5 mg/mL salmon sperm DNA. The membranes
were hybridized with 32P-dCTP-labeled cDNA clones.After removing the clamp, 6 mL of prewarmed (37C)
normal saline was instilled into the abdominal cavity. Portions (0.5 to 2 kB) of mouse Cyr61 were generated
by PCR, and the products confirmed by sequencing. TheThe abdomen was closed, and the rat was placed in a
29C incubator. The rat was sacrificed at two hours. hybridized membranes were washed twice in 0.1 SSC
and 0.1% SDS at 50C. Loading of RNA was normalizedAdditional mice and rats were subjected to bilateral
ischemia. Animals were sacrificed from 0.5 to 72 hours by rehybridizing with glyceraldehydes-3-phosphate de-
hydrogenase (GAPDH).after injury. Sham-treated animals went through the
same surgical procedure as the other animals, including
Antibody productionblunt dissection of the renal pedicle; however, renal
clamps were not applied. A peptide corresponding to the C-terminus of mouse/
rat Cyr61 (CPHPNEASFRLYSLFNDIHKFRD) was syn-A rat model of volume depletion was induced by two
20 mg/kg intraperitoneal injections of furosemide (at 0 thesized and conjugated to keyhole limpet hemacyanin
by cross-linking with m-maleimidobenzoyl-N-hydroxy-and 8 hours), and maintained by placing the animals on
Muramatsu et al: Cyr61 in acute renal failure 1603
succinimide ester (Quality Controlled Biochemicals, Inc., in paraffin. Tissue sections (3 m) were processed for
in situ hybridization and evaluated with 35S-labeled senseHopkinton, MA, USA). Rabbits were immunized and
boosted subcutaneously with the peptide-KLH conju- and anti-sense riboprobes according to Wilkinson and
Green [16].gate. Rabbit sera were purified by affinity chromatogra-
phy, using the immunizing peptide coupled to thiol-reac- For nonradioactive in situ hybridization, tissues were
fixed and pretreated as for 35S-labeled probes. Digoxi-tive beads (Quality Controlled Biochemicals, Inc.). In
some studies, the antibody was preabsorbed with anti- genin-labeled single-stranded RNA probes were pre-
pared by Lofstrand Labs using the same probe as forgenic peptide coupled to cyanogen bromide-activated
Sepharose 4B beads (Amersham Pharmacia, Piscataway, 35S-labeling, diluted to 2 g/mL in hybridization buffer,
heated to 95C for three minutes, and immediatelyNJ, USA).
placed on ice until used. Probes (100 L/slide) were
Western blot analysis added to ethanol-dehydrated tissues, sections covered
with parafilm, and hybridizations performed at 60CKidney tissue was homogenized in tissue protein ex-
traction reagent (T-PER; Pierce, Rockford, IL, USA) overnight in a humidified chamber. The next morning,
tissues were rinsed with PBS and digested with RNase Acontaining protease inhibitors (Complete mini protease
inhibitor cocktail tablets; Roche, Mannheim, Germany) (20 g/mL) for 30 minutes at 37C. Slides were then
rinsed with PBS and washed twice with 2  SSC for fiveat 4C. The homogenate was centrifuged at 13,000 rpm
for 10 minutes, and the supernatant was equilibrated minutes at 55C, twice with 1  SSC for five minutes at
55C, twice with 0.5  SSC for five minutes at 55C,with RIPA buffer [150 mmol/L NaCl, 50 mmol/L Tris pH
8.0, 0.1% SDS, 1% Nonidet P-40, 0.5% deoxycholoate, twice with 0.1  SSC in 0.1% SDS for five minutes at
55C, and three times with PBS for five minutes at room1 mmol/L phenylmethylsulfonyl fluoride (PMSF)], and
then incubated with heparin beads (Heparin Sepharose temperature. For visualization, sections were first blocked
with maleic acid buffer (MAB; 0.1 mol/L maleic acid6 Fast Flow, Amersham Pharmacia) at a volume ratio
of 1:20 at 4C for one hour. The beads were washed and 0.15 mol/L NaCl adjusted to pH 7.5 with NaOH)
containing Tween-20 (0.1%), levamisole (0.5 mg/mL),twice with excess RIPA buffer containing 400 mmol/L
NaCl. Proteins were eluted with RIPA buffer at 800 blocking reagent (2%, Roche), and heat-inactivated
sheep serum (10%) for two hours. Blocking buffer wasmmol/L NaCl and then the eluate was incubated in
Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) removed and replaced with MAB blocking buffer con-
taining antibody (anti-digoxigenin-AP Fab fragments;with 200 mmol/L dithiothreitol (DTT) at 60C for 15
minutes. The samples were incubated at 4C overnight, Roche), which was diluted 1:4000. Sections were incu-
bated overnight at 4C in a humidified chamber. Slidesbriefly centrifuged, and the supernatant stored in 4C.
The protein content of the homogenate (before bead were then washed three times for 15 minutes each in
MAB containing Tween-20 (0.1%) and then once inpurification) was determined according to the Bradford
method using bovine serum albumin (BSA) as a stan- water with Tween-20 (0.1%) for five minutes. Slides were
then drained, immediately covered with BM purple APdard. Heparin bead purified cell lysate was fractionated
on a 12% polyacrylamide gel and transferred to a polyvi- substrate (Roche), and incubated for three days at room
temperature in a humidified chamber. Reactions werenylidene difluoride (PVDF) membrane (Immobilon-P;
Millipore, Bedford, MA, USA). The membrane was stopped with ethylenediaminetetraacetic acid (EDTA;
1 mmol/L) in PBS, and tissues mounted.blocked by incubation overnight in 5% (wt/vol) nonfat
dry milk in Tris-buffered saline containing 0.1% Tween
Urine collection20 (TBS-T). The membrane was incubated with of 0.75
g/mL primary antibody for two hours, washed, and Male Sprague-Dawley rats were placed in metabolic
cages (Nalgene, Rochester, NY, USA), and urine wasthen incubated with horseradish peroxidase-conjugated
goat anti-rabbit immunoglobulins antibody (Dako A/S, collected at specified time intervals before or after 30
minutes of bilateral renal ischemia. Urine was collectedGlostrup, Denmark) for one hour at a dilution of 1:2000.
The reaction products were visualized by chemilumines- into vials containing ice-cold 1 mol/L Tris-HCl (pH 6.8),
0.1 mg/mL PMSF, 1 g/mL leupeptin, and 1 mmol/Lcence (ECL-plus; Amersham) using BioMax MR film
(Eastman Kodak, Rochester, NY, USA). sodium azide [17]. The urine samples were centrifuged
at 1000  g at 4C for 20 minutes to remove cells, casts,
In situ hybridization and other debris, and the supernatant was used for the
assay. In preliminary studies, we could not detect Cyr61Rat kidneys were perfused with cold saline, then 4%
cold paraformaldehyde, and removed. The resected kid- protein in the urinary pellet (data not shown). Urinary
creatinine was measured by an Astra 8 autoanalyzerneys were cut in half, fixed overnight in 4% paraformal-
dehyde, washed in phosphate-buffered saline (PBS), de- (Beckman Instruments, Inc., Fullerton, CA, USA) to
standardize the analysis of urine samples. To control forhydrated through a graded ethanol series, and embedded
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Fig. 2. Northern blot analysis of Cyr61 expression in adult rat tissues
following renal ischemia. Organs were obtained from rats subjected to
sham surgery or 40 minutes of bilateral ischemia and four hours of
reperfusion. Northern blotting and hybridization procedures are the
same as described in the legend to Figure 1. Abbreviations are: H,
heart; Lu, lung; K, kidney; Sp, spleen; M, skeletal muscle (pretibial
muscle); Li, liver.
Fig. 1. Northern blot analysis of Cyr61 expression following ischemia
reperfusion. Kidney tissue was obtained from normal or sham-operated
male Sprague-Dawley rats, or 2, 4, 24, and 72 hours after 40 minutes
of bilateral renal ischemia. Northern blots containing 7 to 10 g of total
RNA from whole kidney (A) or outer medulla (B) were hybridized
with a 32P-labeled portion of rat Cyr61 or GAPDH cDNA, washed,
and the signal detected by autoradiography. Equality of RNA loading
was confirmed using GAPDH (data not shown).
urinary concentration, urine samples containing 0.15 mg
creatinine were purified by binding to heparin-sepharose
beads and analyzed as described above (Western blot Fig. 3. Heparin bead capture for Cyr61 protein detection. Kidney tis-
analysis). The fractional excretion of sodium (FENa)was sues were obtained from normal mice or four hours after 40 minutes
of bilateral renal ischemia (I/R). Kidney tissue homogenates were runmeasured using a standard formula [FENa  UNa * PCr/
as is (10 g per lane; lanes 1), or were purified by incubating 200 g(PNa * UCr)], where FE is fractional excretion, U and P protein with heparin beads, washing with 150 mmol/L (lanes 2) or 400
are urine and plasma, respectively, and Cr is creatinine. mmol/L (lanes 3) NaCl-RIPA buffer, then eluting with 800 mmol/L
NaCl-RIPA buffer followed by Laemmli sample buffer (see Methods
section). Samples were analyzed by SDS-PAGE and Western blotting,
using an affinity-purified antibody to mouse/rat Cyr61.RESULTS
Temporal expression of Cyr61 mRNA
The results of the representational difference analysis pression in spleen is controversial [18, 20]. We analyzed
were confirmed by Northern blotting (Fig. 1). There was the expression of Cyr61 in adult rat tissues (Fig. 2). In
a dramatic up-regulation of rat Cyr61 mRNA abundance animals subjected to sham surgery, Cyr61 mRNA abun-
in the whole kidney and the renal outer medulla at two dance was highest in lung as previously described [18],
hours following bilateral renal ischemia, with a decline but also detected at low levels in heart, kidney, and
by four hours, and a return toward normal at 24 to 72 muscle. Four hours following bilateral renal ischemia,
hours of reperfusion. the abundance of Cyr61 mRNA increased markedly in
the kidney, but not in the other organs sampled.
Organ specific expression of Cyr61 mRNA
Optimization of Cyr61 protein assayCyr61 mRNA has been detected by RNAse protection
assays [18] or Northern blotting [19–21] in normal lung, Western blotting analysis using an affinity-purified an-
tibody to Cyr61 detected several non-specific bands inheart, skeletal muscle, and kidney, but not in liver. Ex-
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Fig. 4. Time course of Cyr61 protein expres-
sion following renal ischemia. Balb/c mice
were subjected to 40 minutes of bilateral isch-
emia then 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours
of reperfusion. Kidney tissue homogenates
(200 g protein per lane) were incubated with
heparin beads, washed with 400 mmol/L NaCl
RIPA buffer, then eluted with 800 mmol/L
NaCl-RIPA buffer followed by Laemmli sam-
ple buffer. Samples were analyzed as de-
scribed in the legend to Figure 3. Abbrevia-
tions are: N, normal kidney. S, sham operated
kidney obtained four hours after the surgery.
normal and in ischemic/reperfused kidney, without an
obvious increase in any of the bands (Fig. 3; lanes 1).
Cyr61 binds heparin with high affinity and heparin affin-
ity beads have been used to concentrate Cyr61 from
tissue culture conditioned media, and purify recombi-
nant Cyr61 [19, 22, 23]. Therefore, heparin bead capture
was used to concentrate Cyr61 and remove non-specific
proteins. Tissue homogenates were incubated with hepa- Fig. 5. Organ specificity of Cyr61 protein expression following renal
ischemia. Organs were obtained from male Sprague-Dawley rats sub-rin beads and then washed with 150 or 400 mmol/L NaCl
jected to 40 minutes of bilateral ischemia and six hours of reperfusionbuffer to remove the proteins that did not bind heparin. (I/R 6 h) or 6 hours after sham surgery (Sham). Tissue homogenates
Proteins were eluted using 800 mmol/L NaCl, which in (300 g total protein per lane) were purified as described in Figure 4,
and analyzed by SDS-PAGE and Western blotting. Abbreviations are:previous studies caused peak elution of Cyr61 [19, 22,
H, heart; Lu, lung; K, kidney; Sp, spleen; M, skeletal muscle (pretibial
23], and Laemmli buffer. Washing with a low stringency muscle); Li, liver. For comparison, 1/2, 1/5, 1/10, or 1/20 of the I/R 6 h
kidney homogenates were loaded to the right three lanes.150 mmol/L NaCl buffer decreased the non-specific
bands and allowed detection of a doublet near the ex-
pected size of 42 kD. (Fig. 3; lane 2). The lower band,
but not the higher band, was regulated by renal ischemia.
in kidney and spleen (Fig. 5). Following bilateral renalBy washing the beads under more stringent conditions
ischemia, there was a dramatic up-regulation of Cyr61(400 mmol/L NaCl), we obtained a single band (Fig. 3;
protein in the kidney (20-fold), with more modest in-
lane 3) that was regulated by ischemia, and corresponded
creases in lung and heart. The band was blocked by
to Cyr61 (documented by peptide competition; see Fig. preabsorbtion with antigenic peptide coupled to Sepha-
8). Subsequent studies were performed using a 400 rose beads (data not shown).
mmol/L NaCl wash.
Location of Cyr61 mRNA
Time course of Cyr61 protein expression
Cyr61 mRNA was localized using in situ hybridization
Using these optimized assay conditions, the appear- with both 35S- and digoxigenin-labeled probes in tissue
ance of Cyr61 was studied following 40 minutes of bilat- sections from adult Sprague-Dawley rat kidneys (Fig. 6).
eral renal ischemia. Cyr61 protein was faintly detectable Serial sections were probed with anti-sense and sense
in normal and sham-operated kidney, was increased at probe; sections labeled with sense probes were at back-
one hour, peaked at four to eight hours, and was still ground levels (data not shown). We did not detect any
expressed at 24 hours after ischemia (Fig. 4). The band Cyr61 mRNA in kidney from a normal (Fig. 6A) or
was absent if the primary antibody was preabsorbed with sham-operated rat (Fig. 6B). Two hours after bilateral
antigenic peptide coupled to Sepharose beads (data not ischemia, signal appeared in the outer stripe of the outer
shown). medulla and medullary rays (Fig. 6C), the location of
maximal tubular injury following renal ischemia/reperfu-
Expression of Cyr61 protein in other organs sion [24]. We also performed digoxigenin-labeled in situ
The assay was used to examine the tissue distribution hybridization to examine the cellular localization of
of Cyr61 protein after renal ischemia. In animals sub- Cyr61. Digoxigenin-labeled probe was detected in the
jected to sham surgery, Cyr61 protein was expressed in outer stripe of the outer medulla and medullary rays
(Fig. 6D), the same location as the 35S-labeled probeheart, skeletal muscle, and lung, and at very low levels
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Fig. 6. Localization of renal Cyr61 mRNA by in situ hybridization. Kidneys were obtained from male Sprague-Dawley rats subjected to sham
surgery or 40 minutes of bilateral ischemia and two hours of reperfusion. Each block was probed with anti-sense and sense probe on serial sections.
Detection of the sense probe was at background levels for each treatment (data not shown). (A-C ) 35S-labeled probe. (D-E ) Digoxigenin-labeled
probe. (A) Control normal kidney; (B) 2 hours after sham surgery; (C) 2 hours after renal ischemia. The positive signals for Cyr61 (white granules)
were localized in the outer stripe of the outer medulla and medullary rays. (D) Digoxigenin-labeled probe (black stain) 2 hours after renal ischemia.
(Magnification, 25) E, higher magnification of the square shown in panel D (200)
(Fig. 6C). Under higher magnification (Fig. 6E), Cyr61 lated under these conditions (Fig. 8A). Cyr61 protein
mRNA was primarily expressed in the cytoplasm of was not detected in normal urine, but was detected 24
proximal straight tubules that showed mild injury, al- hours after ischemia (Fig. 7). We then studied the time
though we cannot rule out labeling in other tubular cells. course of appearance of Cyr61. Cyr61 protein was de-
No signals were detected when using digoxigenin-labeled tected as early as three to six hours after renal ischemia
sense probes (data not shown). The distribution suggests (Fig. 8A), peaked at six to nine hours after ischemia,
labeling of the proximal straight tubules in the outer and decreased thereafter. Urine also contained a number
stripe and medullary rays, although other structures in of non-specific higher molecular weight bands; however,
that region also might express Cyr61. only the 42 kD band was absent after preabsorption of
the Cyr61 antiserum with excess Cyr61 peptide (Fig. 8B).
Detection of Cyr61 in urine after ischemia In contrast, neither renal nor urinary Cyr61 was detected
Since Cyr61 is a secreted protein and produced in in rats subjected to volume depletion (Fig. 8A).
tubules following renal ischemia (Fig. 6), we next deter-
mined if Cyr61 could be detected in the urine following
DISCUSSIONrenal injury. The length of bilateral renal ischemia was
Representational difference analysis was used to searchreduced to 30 minutes to obtain sufficient quantities of
urine; however, renal Cyr61 protein was still up-regu- for renal genes whose protein products might serve as
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nea [28]. Cyr61 stimulates migration and adhesion of en-
dothelial cells, platelets, fibroblasts, and vascular smooth
muscle via v3 [28], IIb3 [29], and 61 [30, 31] integrins,
respectively. Cyr61 also is induced by bladder stretch
[32] and hypertonicity [33]. More central to our findings,
Cyr61 promotes healing of a wounded fibroblast mono-
layer [14]; increases fibroblast adherence [30]; causes
cytoskeleton reorganization, formation of filopodia and
focal adhesive complexes [34]; and activates a genetic
program for wound healing [35]. Cyr61 has been detected
locally after wounding in cultured cells and rat tail [14],
vascular injury [36], and bone fractures [37], suggesting
a role in wound healing or tissue remodeling.
In this study, Cyr61 was measured following renal
ischemia and reperfusion. Cyr61 mRNA was easily de-
tected by Northern blotting (Figs. 1 and 2); however,
detection of Cyr61 protein was challenging since several
bands obscured renal Cyr61 (Fig. 3). We exploited the
heparin-binding ability of Cyr61 to develop a sensitive
assay for Cyr61 in tissue homogenates and biological
Fig. 7. Urine Cyr61 before and after renal ischemia. Twenty-four-hour
fluids. At baseline, Cyr61 mRNA abundance was highesturine collections were obtained from three rats (1–3) before and after
30 minutes of bilateral renal ischemia. The urine samples were collected in lung, with lower levels in heart, kidney and muscle
into T-PER buffer containing protease inhibitors. Portions of the urine (Fig. 2), whereas Cyr61 protein was expressed in heart,
supernatant (containing a constant amount of creatinine, see Methods)
with successively lower levels in muscle, lung, kidney,were purified by binding to heparin beads and analyzed by SDS-PAGE
and Western blotting, as described in Figure 4. Two duplicate mem- liver, and spleen. This RNA expression pattern is similar
branes were probed with affinity purified anti-Cyr61 antibody (A) or to previous studies using RNAse protection assays [18]
primary antibody that had been pre-incubated with excess peptide (B).
and Northern blotting [19, 21, 23], although we did not
detect Cyr61 mRNA in spleen [20]. Cyr61 protein has
been detected previously in skeletal muscle, cardiac mus-
cle, and smooth muscle of bronchioles and blood vesselsdiagnostic tests for ARF. Since the role of leukocytes in
human ARF is uncertain and controversial, we wished [38, 39]. The reason for the difference between mRNA
and protein expression is not known, but could be causedto avoid leukocyte genes. Therefore, to examine native
kidney proteins, kidney tissue obtained two hours after by differences in mRNA stability and/or protein turn-
over in different organs [18, 40]. Induction after renalischemia was used, at which time only sparse leukocyte
infiltration has occurred. Using this strategy, we found ischemia was rapid, with peak induction of mRNA at
two hours (Fig. 1) and protein by four hours (Fig. 4).that (1) Cyr61 mRNA was induced in the renal outer
medulla very early after renal ischemia, (2) Cyr61 pro- Following renal ischemia, Cyr61 mRNA was induced in
kidney and not in other organs (Fig. 2), although in-tein increased rapidly after ischemia but not volume
depletion, and (3) that Cyr61 protein could be detected creased protein also could be detected in heart and lung.
Cyr61 up-regulation following injury is similar to thatin the urine from animals early after ischemia.
Cyr61 was first identified as a gene that was activated previously described following wound healing in cultured
cells and rat tail [14], vascular balloon injury [36], andtranscriptionally in the early-intermediate period after
growth factor stimulation of mouse fibroblasts [13]. Sub- bone fractures [37]. Induction of Cyr61 in the lung may
be caused by the lung injury that results from renal isch-sequent studies found that Cyr61 is a secreted, cysteine-
rich, heparin-binding protein that acts as a matrix-associ- emia [41].
In situ hybridization was used to localize sites of Cyr61ated signaling molecule capable of multiple functions
[reviewed in 25]. Cyr61 is a member of the CCN family, mRNA accumulation, a marker of net Cyr61 synthesis
under these conditions of rapid induction. We did nota term that refers to the three original members [Cyr61/
connective tissue growth factor/nephroblastoma overex- detect Cyr61 expression in the control kidney, but did
see enhanced expression primarily in proximal straightpressed (NOV)] of a family of secreted extracellular
growth factors that now includes Wnt-induced secreted tubules in medullary rays and the outer stripe of the
outer medulla (Fig. 6) at two hours after injury. This por-proteins [25, 26]. Cyr61 can promote the proliferation,
migration, and adhesion of endothelial cells and fibro- tion of the kidney sustains the most injury in the ischemia
reperfusion model, and contains proximal straight tu-blasts [23], stimulate growth and differentiation of chon-
drocytes [27], and induce neovascularization of the cor- bules that undergo apoptosis and necrosis, which can be
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Fig. 8. Temporal excretion of urinary Cyr61
protein after renal ischemia and during vol-
ume depletion. Rats were subjected to volume
depletion (VD) or 30 minutes of bilateral isch-
emia and reperfusion (I/R). Kidney homoge-
nates (200 g total protein per lane) were
purified and analyzed as described in Figure
4. Abbreviations are: N, normal; I/R, 30 min-
utes of bilateral ischemia and 24 hours of re-
perfusion; P, positive control, 40-minutes of
bilateral ischemia and six hours of reperfusion.
Urine was collected from the VD and I/R
rats into the collection buffer (Methods), and
analyzed for Cyr61 as in Figure 7. C represents
control urine collected before making VD or
I/R models. Urine from the I/R rat was col-
lected during 3–6, 6–9, 9–12, 12–18, and 18–24
hours after 30 minutes of bilateral ischemia.
No urine was produced during the first three
hours. The specific signals for Cyr61 protein
(arrows) obtained with the anti-rat/mouse
Cyr61 antiserum (A) were prevented by pre-
absorption with the corresponding peptide (B).
easily detected at two and four hours after reperfusion hours, peaked at six to nine hours, but remained detect-
able from nine to 24 hours after 30 minutes of bilateral[24, 42, 43]. One previous study has detected weak ex-
pression of Cyr61 in proximal tubules of the newborn renal ischemia. The clinical differentiation of ARF (that
is, acute tubular necrosis) from volume depletion maymouse kidney [38]. Nahm et al have recently shown that
hypertonicity increases Cyr61 mRNA in cultured inner be difficult, requiring measurement of FENa and/or fluid
administration. Therefore, we examined the effect ofmedullary collecting duct cells [33]. We did not detect
Cry61 mRNA in the inner medulla of normal or ischemic volume depletion on Cyr61. Neither renal nor urinary
Cyr61 was increased following volume depletion. Re-kidneys (Fig. 6), or Cyr61 protein in the kidney [3] fol-
lowing volume depletion (Fig. 8), which increases medul- cently, hepatocyte growth factor (HGF), kidney injury
molecule-1 (KIM-1), IL-18, pro-inflammatory cytokines,lary tonicity. The different results may be caused by
differences in experimental models, assays, or timing of and actin have been studied as potential ARF disease
markers [47–49]. All are elevated in the urine followingassays. Nahm et al used cultured cells very early after
hypertonic stress, whereas we waited 24 hours for the human ARF, and are currently being evaluated for sensi-
tivity and specificity. HGF is stored in the normal kidneyanimals to equilibrate into steady state after volume
depletion. and released upon injury, whereas KIM-1 is markedly
up-regulated in the proximal tubule of post-ischemic re-Early detection of ARF might be aided by discovery
of a serum marker akin to troponin for myocardial in- generating kidneys, although not as rapidly as Cyr61.
How early these urinary markers increase following renalfarction. Serum creatinine, while used clinically, is a sub-
optimal marker because it is influenced by non-renal damage is unknown. Since Cyr61 is induced rapidly fol-
lowing renal injury, but not following pre-renal azotemia,factors [3]. The classic ARF marker is the fractional
excretion of sodium (FENa), which was originally de- it has the characteristics of an early disease marker, per-
haps similar to troponin following myocardial infarction.scribed as 1% in volume depletion and 1% in ARF
[44]. However, FENa is also low in nonoliguric ARF, Previous studies have suggested that Cyr61 acts locally
because secreted Cyr61 is tightly bound to the cell sur-sepsis, urinary tract obstruction, acute glomerulonephri-
tis, hepatorenal syndrome, and renal allograft rejection face and extracellular matrix and was not detected in
conditioned media [22, 38]. Hence, it was surprising to[45]. Attempts to use structural components of the kid-
ney, such as N-acetyl-beta-D-glucosamine, as injury find Cyr61 in urine. The role of urinary Cyr61 is un-
known, but we speculate that it might provide an impor-markers have failed because these markers are too sensi-
tive and cannot differentiate normal from disease states tant signal to a downstream nephron segment.
In conclusion, Cyr61 is rapidly induced in the kidney,[46]. Since Cyr61 is a secreted protein that is rapidly
induced in the outer medulla following renal injury, we primarily in proximal straight tubules, by renal ischemia
but not volume depletion. Cyr61 is secreted into the urinetested if Cyr61 could be detected in urine. We detected
an increase in urinary Cyr61 (Figs. 7 and 8) after renal early after renal ischemia, but not volume depletion.
Because of its rapid induction, Cyr61 might serve as aninjury. Urinary Cyr61 was increased within three to six
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independent of its carboxy-terminal domain. J Biol Chem 276:early disease marker for renal injury. Thus, urinary Cyr61
21943–21950, 2001
might detect subtle renal injury after contrast administra- 16. Wilkinson D, Green J: In situ hybridization and the three-dimen-
tion, chemotherapy, transplantation, vascular surgery, or sional reconstruction of serial sections, in Postimplantation Mam-
malian Embroyos, edited by Coop AJ, Cockroft DL, London,in kidney donors. Cyr61 might also detect early ARF in
Oxford University Press, 1990, pp 155–171high-risk patients, for example, with multi-organ failure 17. McKee JA, Kumar S, Ecelbarger CA, et al: Detection of Na(	)
in the ICU. It is hoped that early detection of ARF will transporter proteins in urine. J Am Soc Nephrol 11:2128–2132, 2000
18. O’Brien TP, Yang GP, Sanders L, et al: Expression of cyr61, alead to earlier treatment, thus enhancing our ability to
growth factor-inducible immediate-early gene. Mol Cell Biol 10:develop beneficial therapies. 3569–3577, 1990
19. Kolesnikova TV, Lau LF: Human CYR61-mediated enhance-
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